Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: May 29, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
12
2023 to 2026
Breakthrough
1
Accelerated
0
Priority review
2
Orphan
0
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 4 | 0 |
| 2024 | 0 | 1 |
| 2025 | 6 | 0 |
| 2026 | 1 | 0 |
12 approvals
Newest first. Hover a badge for what it means.
- Cypsedo (Cipepofol) · HaiscoMay 29, 2026
To induce general anesthesia in adults undergoing surgery
- Bondlido (Lidocaine) · Medrx USASep 24, 2025Original approval · NDA 215029Approval letter
- Vyscoxa (Celecoxib) · Carwin Pharm AssocJul 29, 2025Original approval · NDA 211759Approval letter
- Xifyrm (Meloxicam) · AzurityJun 5, 2025Original approval · NDA 218395Approval letter
- Qamzova (Meloxicam) · Nanjing DelovaApr 22, 2025Original approval · NDA 217593Approval letter
- Symbravo (Meloxicam, Rizatriptan Benzoate) · AxsomeJan 30, 2025Original approval · NDA 215431Approval letter
- Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
To treat moderate to severe acute pain
- Letybo (Letibotulinumtoxina-Wlbg) · Hugel INCFeb 29, 2024
To temporarily improve the appearance of moderate-to-severe glabellar lines
- Coxanto (Oxaprozin) · SolubiomixOct 20, 2023Original approval · NDA 217927Approval letter
- Combogesic Iv (Acetaminophen, Ibuprofen Sodium) · HikmaOct 17, 2023Original approval · NDA 215320Approval letter
- Brixadi (Buprenorphine) · BraeburnMay 23, 2023
- Combogesic (Acetaminophen, Ibuprofen) · Aft Pharms USMar 1, 2023Original approval · NDA 209471Approval letter
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.